These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 36173008)

  • 1. Epidemiology and treatment utilization for Canadian patients with migraine: a literature review.
    Graves EB; Gerber BR; Berrigan PS; Shaw E; Cowling TM; Ladouceur MP; Bougie JK
    J Int Med Res; 2022 Sep; 50(9):3000605221126380. PubMed ID: 36173008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A global real-world assessment of the impact on health-related quality of life and work productivity of migraine in patients with insufficient versus good response to triptan medication.
    Lombard L; Farrar M; Ye W; Kim Y; Cotton S; Buchanan AS; Jackson J; Joshi S
    J Headache Pain; 2020 Apr; 21(1):41. PubMed ID: 32349662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost of health care among patients with chronic and episodic migraine in Canada and the USA: results from the International Burden of Migraine Study (IBMS).
    Stokes M; Becker WJ; Lipton RB; Sullivan SD; Wilcox TK; Wells L; Manack A; Proskorovsky I; Gladstone J; Buse DC; Varon SF; Goadsby PJ; Blumenfeld AM
    Headache; 2011; 51(7):1058-77. PubMed ID: 21762134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct cost and healthcare resource utilization of patients with migraine before treatment initiation with calcitonin gene-related peptide monoclonal antibodies by the number of prior preventive migraine medication classes.
    Foster SA; Hoyt M; Ye W; Mason O; Ford JH
    Curr Med Res Opin; 2022 May; 38(5):653-660. PubMed ID: 34761723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An economic evaluation of rizatriptan in the treatment of migraine.
    Thompson M; Gawel M; Desjardins B; Ferko N; Grima D
    Pharmacoeconomics; 2005; 23(8):837-50. PubMed ID: 16097844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The burden of medication overuse headache and patterns of switching and discontinuation among triptan users: a systematic literature review.
    Deighton AM; Harris LA; Johnston K; Hogan S; Quaranta LA; L'Italien G; Coric V
    BMC Neurol; 2021 Nov; 21(1):425. PubMed ID: 34727873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rates and predictors of starting a triptan: results from the American Migraine Prevalence and Prevention Study.
    Bigal ME; Buse DC; Chen YT; Golden W; Serrano D; Chu MK; Lipton RB
    Headache; 2010 Oct; 50(9):1440-8. PubMed ID: 20533956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of NSAID and Triptan use on developing chronic migraine: results from the American Migraine Prevalence and Prevention (AMPP) study.
    Lipton RB; Serrano D; Nicholson RA; Buse DC; Runken MC; Reed ML
    Headache; 2013; 53(10):1548-63. PubMed ID: 23992516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Healthcare resource utilization and associated costs among patients with migraine in Finland: A retrospective register-based study.
    Kosunen M; Rossi J; Niskanen S; Metsä R; Kainu V; Lahelma M; Isomeri O
    PLoS One; 2024; 19(3):e0300816. PubMed ID: 38507402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triptans in the Acute Treatment of Migraine: A Systematic Review and Network Meta-Analysis.
    Cameron C; Kelly S; Hsieh SC; Murphy M; Chen L; Kotb A; Peterson J; Coyle D; Skidmore B; Gomes T; Clifford T; Wells G
    Headache; 2015; 55 Suppl 4():221-35. PubMed ID: 26178694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Access to Triptans for Acute Episodic Migraine: A Qualitative Study.
    Khan S; Mascarenhas A; Moore JE; Knowles S; Gomes T
    Headache; 2015; 55 Suppl 4():199-211. PubMed ID: 26178420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors associated with triptan use in episodic migraine: results from the American Migraine Prevalence and Prevention Study.
    Chu MK; Buse DC; Bigal ME; Serrano D; Lipton RB
    Headache; 2012 Feb; 52(2):213-23. PubMed ID: 22413150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rates and reasons for discontinuation of triptans and opioids in episodic migraine: results from the American Migraine Prevalence and Prevention (AMPP) study.
    Holland S; Fanning KM; Serrano D; Buse DC; Reed ML; Lipton RB
    J Neurol Sci; 2013 Mar; 326(1-2):10-7. PubMed ID: 23394974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of healthcare resource utilization and costs among patients with migraine with potentially adequate and insufficient triptan response.
    Marcus SC; Shewale AR; Silberstein SD; Lipton RB; Young WB; Viswanathan HN; Doshi JA
    Cephalalgia; 2020 Jun; 40(7):639-649. PubMed ID: 32223301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Similarities and differences between chronic migraine and episodic migraine.
    Ferrari A; Leone S; Vergoni AV; Bertolini A; Sances G; Coccia CP; Ottani A; Pinetti D; Sternieri E
    Headache; 2007 Jan; 47(1):65-72. PubMed ID: 17355496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utilisation of prescription and over-the-counter triptans: a cross-sectional study in Stockholm, Sweden.
    Frisk P; Sporrong SK; Ljunggren G; Wettermark B; von Euler M
    Eur J Clin Pharmacol; 2016 Jun; 72(6):747-54. PubMed ID: 26922586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triptans for Acute Migraine: Drug Class Review to Help Inform Policy Decisions.
    Knowles S; Oh P; Gomes T;
    Headache; 2015; 55 Suppl 4():191-8. PubMed ID: 26178586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment pattern and health care resource utilization for Taiwanese patients with migraine: a population-based study.
    Wang YF; Wang SJ; Huang YH; Chen YT; Yen YC; Shia BC; Tsai CW; Chan HF; Panni T; Dell'Agnello G
    Front Neurol; 2023; 14():1222912. PubMed ID: 37654430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A real-world study on unmet medical needs in triptan-treated migraine: prevalence, preventive therapies and triptan use modification from a large Italian population along two years.
    Piccinni C; Cevoli S; Ronconi G; Dondi L; Calabria S; Pedrini A; Esposito I; Favoni V; Pierangeli G; Cortelli P; Martini N
    J Headache Pain; 2019 Jun; 20(1):74. PubMed ID: 31248360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drugs for the acute treatment of migraine in children and adolescents.
    Richer L; Billinghurst L; Linsdell MA; Russell K; Vandermeer B; Crumley ET; Durec T; Klassen TP; Hartling L
    Cochrane Database Syst Rev; 2016 Apr; 4(4):CD005220. PubMed ID: 27091010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.